Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Absolute Lymphocyte Count As a Novel Prognostic Predictor Compared to Minimal Residual Disease and Molecular Status in Patients with Acute Myeloid Leukemiatreated with Intensive Chemotherapy

Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Federica Ardizzoia, Chiara Sartor, Sarah Parisi, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2024) 144 (Supplement 1): 6116.

https://doi.org/10.1182/blood-2024-209333

Published: 2024

Journal Articles

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2024-205994

Published: 2024

Journal Articles

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Blood (2024) 144 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2024-210315

Published: 2024

Journal Articles

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Blood (2023) 142 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2023-190091

Published: 2023

Journal Articles

Iron-Related Laboratory Profile May Predict Response and MRD Negativity Rate in Acute Myeloid Leukemia Patients

Federico Zingarelli, Gianluca Cristiano, Chiara Sartor, Letizia Zannoni, Jacopo Nanni, Martina Barone, Lorenza Bandini, Emanuela Ottaviani, Valentina Robustelli, Nicoletta Testoni, Mario Arpinati, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2023) 142 (Supplement 1): 6052.

https://doi.org/10.1182/blood-2023-188709

Published: 2023

Journal Articles

Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia

Dorian Forte, Filippo Maltoni, Samantha Bruno, Paulina Garcia-Gonzalez, Gianluca Cristiano, Chiara Sartor, Simona Soverini, Lucia Catani, Rafael José Argüello, Michele Cavo, Antonio Curti

Blood (2023) 142 (Supplement 1): 1598.

https://doi.org/10.1182/blood-2023-185909

Published: 2023

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2023-184741

Published: 2023

Journal Articles

Impact of MTHFR Polymorphisms C677T and A1298C in Acute Lymphoblastic Leukemia and Burkitt Lymphoma Patients Exposed to Methotrexate and Asparaginase

Chiara Sartor, Benedetta Pagano, Soara Menabò, Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Sarah Parisi, Alessandro Broccoli, Stefania Paolini, Pier Luigi Zinzani, Michele Cavo, Cristina Papayannidis, Antonio Curti

Blood (2023) 142 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2023-189495

Published: 2023

Journal Articles

Absolute Lymphocyte Count Is an Independent Survival Predictor in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Chiara Sartor, Sarah Parisi, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2022) 140 (Supplement 1): 11793–11794.

https://doi.org/10.1182/blood-2022-167035

Published: 2022

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

Journal Articles

A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure

Chiara Sartor, Lorenzo Brunetti, Ernesta Audisio, Alessandro Cignetti, Letizia Zannoni, Gianluca Cristiano, Jacopo Nanni, Emanuela Ottaviani, Lorenza Bandini, Sarah Parisi, Stefania Paolini, Sofia Sciabolacci, Valeria Cardinali, Cristina Papayannidis, Michele Cavo, Maria Paola Martelli, Antonio Curti

Blood (2022) 140 (Supplement 1): 9034–9035.

https://doi.org/10.1182/blood-2022-165914

Published: 2022

Journal Articles

Extracellular Vesicle-Based Liquid Biopsy Shows Clinical Relevance and Reveals Links with Single-Cell Metabolic Signature in Acute Myeloid Leukemia

Dorian Forte, Rafael J. Argüello, Roberto Maria Pellegrino, Husam B.R. Alabed, Martina Barone, Samantha Bruno, Francesco Fabbri, Ivan Vannini, Gianluca Cristiano, Sandra Buratta, Lorena Urbanelli, Carla Emiliani, Michele Cavo, Antonio Curti

Blood (2022) 140 (Supplement 1): 3389–3390.

https://doi.org/10.1182/blood-2022-165850

Published: 2022

Journal Articles

Parallel Detection of Single-Cells and Extracellular Vesicles from Bone Marrow and Peripheral Blood Reveals Asymmetric Immunometabolic Profile in Acute Myeloid Leukemia

Dorian Forte, Rafael J. Argüello, Martina Barone, Samantha Bruno, Gianluca Cristiano, Michele Cavo, Antonio Curti

Blood (2022) 140 (Supplement 1): 9158–9159.

https://doi.org/10.1182/blood-2022-166761

Published: 2022

Journal Articles

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

Giovanni Marconi, Lorenza Bandini, Agnese Patuelli, Chiara Sartor, Sarah Parisi, Jacopo Nanni, Gianluca Cristiano, Letizia Zannoni, Giorgia Simonetti, Maria Teresa Bochicchio, Emanuela Ottaviani, Giovanni Martinelli, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2021-149450

Published: 2021

Journal Articles

Circulating Extracellular Vesicles from Acute Myeloid Leukemia Patients Drive Distinct Metabolic Profile of Leukemic Cells and Reveal Crucial Lipidomic Biomarkers

Dorian Forte, Roberto Maria Pellegrino, Francesco Fabbri, Ivan Vannini, Samantha Bruno, Giulia Corradi, Rafael J. Argüello, Gianluca Cristiano, Sandra Buratta, Lorena Urbanelli, Carla Emiliani, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 3471.

https://doi.org/10.1182/blood-2021-150339

Published: 2021

Journal Articles

An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients

Jacopo Nanni, Cristina Papayannidis, Gianluca Cristiano, Giovanni Marconi, Chiara Sartor, Sarah Parisi, Rashed Saed, Letizia Zannoni, Emanuela Ottaviani, Lorenza Bandini, Nicoletta Testoni, Carmen Baldazzi, Paolo Ricci, Chiara Di Giovanni Bezzi, Rania Abd-alatif, Stefania Paolini, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2021-149535

Published: 2021

Journal Articles

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Blood (2021) 138 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2021-149459

Published: 2021

Journal Articles

A Three-Gene Immune Signature Including IDO1 , BIN1 and PLXNC1 Predicts Survival in Acute Myeloid Leukemia

Simone Ragaini, MD, Sarah Wagner, BSc MSc, Giovanni Marconi, MD, Sarah Parisi, MDPhD, Chiara Sartor, MD, Jacopo Nanni, MD, Gianluca Cristiano, MD, Annalisa Talami, MD, Matteo Olivi, MD, Darina Ocadlikova, PhD, Marilena Ciciarello, PhD, Giulia Corradi, PhD, Emanuela Ottaviani, Cristina Papayannidis, MDPhD, Stefania Paolini, MD PhD, Jayakumar Vadakekolathu, PhD, Michele Cavo, Sergio Rutella, MDPhDFRCPath, Antonio Curti, MDPhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139665

Published: 2020

Journal Articles

Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting

Jacopo Nanni, MD, Cristina Papayannidis, MD PhD, Gianluca Cristiano, MD, Giovanni Marconi, MD, Chiara Sartor, MD, Sarah Parisi, MDPhD, Emanuela Ottaviani, Lorenza Baldini, MSc, Nicoletta Testoni, Carmen Baldazzi, PhD, Paolo Ricci, MD, Chiara Di Giovanni Bezzi, MD, Rania Abd-alatif, MD, Stefania Paolini, MD PhD, Michele Cavo, Antonio Curti, MDPhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-138719

Published: 2020

NARROW

Absolute Lymphocyte Count As a Novel Prognostic Predictor Compared to Minimal Residual Disease and Molecular Status in Patients with Acute Myeloid Leukemiatreated with Intensive Chemotherapy

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Iron-Related Laboratory Profile May Predict Response and MRD Negativity Rate in Acute Myeloid Leukemia Patients

Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Impact of MTHFR Polymorphisms C677T and A1298C in Acute Lymphoblastic Leukemia and Burkitt Lymphoma Patients Exposed to Methotrexate and Asparaginase

Absolute Lymphocyte Count Is an Independent Survival Predictor in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure

Extracellular Vesicle-Based Liquid Biopsy Shows Clinical Relevance and Reveals Links with Single-Cell Metabolic Signature in Acute Myeloid Leukemia

Parallel Detection of Single-Cells and Extracellular Vesicles from Bone Marrow and Peripheral Blood Reveals Asymmetric Immunometabolic Profile in Acute Myeloid Leukemia

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

Circulating Extracellular Vesicles from Acute Myeloid Leukemia Patients Drive Distinct Metabolic Profile of Leukemic Cells and Reveal Crucial Lipidomic Biomarkers

An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

A Three-Gene Immune Signature Including IDO1 , BIN1 and PLXNC1 Predicts Survival in Acute Myeloid Leukemia

Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only